298 related articles for article (PubMed ID: 33535953)
1. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.
Giardina SF; Valdambrini E; Warren JD; Barany F
Curr Cancer Drug Targets; 2021; 21(4):306-325. PubMed ID: 33535953
[TBL] [Abstract][Full Text] [Related]
2. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting of the cancer epigenome.
Mabe NW; Perry JA; Malone CF; Stegmaier K
Nat Cancer; 2024 Jun; 5(6):844-865. PubMed ID: 38937652
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics and oncology.
Mummaneni P; Shord SS
Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
[TBL] [Abstract][Full Text] [Related]
6. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
Webb T; Craigon C; Ciulli A
Bioorg Med Chem Lett; 2022 May; 63():128653. PubMed ID: 35257896
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
10. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
Strauss J; Figg WD
Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets for epigenetic therapy of cancer.
Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in cancer.
Sharma S; Kelly TK; Jones PA
Carcinogenesis; 2010 Jan; 31(1):27-36. PubMed ID: 19752007
[TBL] [Abstract][Full Text] [Related]
13. Role of epigenome in tumorigenesis and drug resistance.
Hu Q; Baeg GH
Food Chem Toxicol; 2017 Nov; 109(Pt 1):663-668. PubMed ID: 28709969
[TBL] [Abstract][Full Text] [Related]
14. Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi S
Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
[TBL] [Abstract][Full Text] [Related]
15. The timeline of epigenetic drug discovery: from reality to dreams.
Ganesan A; Arimondo PB; Rots MG; Jeronimo C; Berdasco M
Clin Epigenetics; 2019 Dec; 11(1):174. PubMed ID: 31791394
[TBL] [Abstract][Full Text] [Related]
16. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
Lin X; Xiang H; Luo G
Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
[TBL] [Abstract][Full Text] [Related]
17. Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy.
Hussain S; Tulsyan S; Dar SA; Sisodiya S; Abiha U; Kumar R; Mishra BN; Haque S
Semin Cancer Biol; 2022 Aug; 83():441-451. PubMed ID: 34182144
[TBL] [Abstract][Full Text] [Related]
18. Long Non-coding RNAs and Drug Resistance.
Pan JJ; Xie XJ; Li X; Chen W
Asian Pac J Cancer Prev; 2015; 16(18):8067-73. PubMed ID: 26745040
[TBL] [Abstract][Full Text] [Related]
19. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy.
Komar D; Juszczynski P
Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
